Related Experiment Videos
Structure-activity relationship studies: M2 and CCR5 receptor antagonists.
Craig D Boyle1, Anandan Palani
1Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Current Topics in Medicinal Chemistry
|May 29, 2003
Summary
Researchers developed potent, selective antagonists for G-protein-coupled receptors, specifically M(2) muscarinic and CCR5 chemokine receptors, addressing challenges in subtype selectivity for therapeutic applications.
Area of Science:
- Pharmacology
- Molecular Biology
- Drug Discovery
Background:
- G-protein-coupled receptors (GPCRs) mediate cellular responses to various signaling molecules.
- GPCRs share a conserved structure with seven transmembrane alpha-helices.
- Receptor desensitization involves carboxyl-terminal phosphorylation and cysteine sites.
Purpose of the Study:
- To develop potent and selective low molecular weight antagonists for M(2) muscarinic and CCR5 chemokine receptors.
- To explore the therapeutic potential of these novel antagonists.
- To detail structure-activity relationships (SAR) for optimizing antagonist properties.
Main Methods:
- High-throughput screening of sample collections to identify initial lead compounds.
- Structure-activity relationship studies to optimize potency and selectivity.
- Focus on overcoming subtype selectivity challenges, particularly M(2) vs. M(1) and CCR5 vs. M(2).
Main Results:
- Identification of initial lead compounds with broad GPCR affinity.
- Optimization of lead compounds to achieve potent and selective antagonists for M(2) and CCR5 receptors.
- Detailed SAR analysis guiding the development of selective agents.
Conclusions:
- Potent and selective antagonists for M(2) muscarinic and CCR5 chemokine receptors were successfully developed.
- Overcoming subtype selectivity was a critical challenge addressed through SAR studies.
- The developed antagonists hold potential for therapeutic applications.